Summit Presents In Vivo Proof of Concept Data for New Mechanism Antibiotics Targeting Enterobacteriaceae in Oral Session at E...
April 14 2019 - 07:42AM
Summit Therapeutics plc (‘Summit’ or the
‘Company’)
Summit Presents In Vivo Proof of Concept Data for New
Mechanism Antibiotics Targeting Enterobacteriaceae in Oral Session
at ECCMID 2019
- DDS-04 Series Cures Enterobacteriaceae Infection in Animal
Model
- Potential in Lung, Bloodstream and Urinary Tract
Infections
- Activity Shown Against Resistant and Non-Resistant
Strains
- Enterobacteriaceae are Gram-Negative Bacteria that Cause a
Large Number of Serious Infections
Oxford, UK, and Cambridge, MA, US, 14 April
2019 – Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM), a
leader in new mechanism antibiotic innovation, today presented in
vivo proof of concept data for the DDS-04 series of new mechanism
antibiotics targeting Enterobacteriaceae in an oral session at the
29th European Congress of Clinical Microbiology & Infectious
Diseases (‘ECCMID’) in Amsterdam.
Enterobacteriaceae are a family of Gram-negative
bacteria responsible for a large number of severe and often deadly
infections. In the data presented, a DDS-04 series compound cured
infection in a translationally-relevant animal model of urinary
tract infection, one of the major sites for Enterobacteriaceae
infection. Therapeutic concentrations of the DDS-04 compound were
also observed in other major sites in the animal model where
life-threatening Enterobacteriaceae infections occur, including the
lungs and the bloodstream.
“Patients with Enterobacteriaceae infections are
increasingly at risk for poor outcomes due to the spread of
antimicrobial resistance,” said Dr David
Roblin, President of R&D of Summit. “Mainstay treatments
are losing their effectiveness, and patients do not have the luxury
of time to fail antibiotic therapy. There is a pressing need for
new, targeted Enterobacteriaceae antibiotics that can serve to
improve patient outcomes.”
The DDS-04 series acts via LolCDE, a novel
bacterial target. The LolCDE site of DDS-04 series activity is
conserved in the majority of therapeutically important
Enterobacteriaceae, resulting in targeted spectrum compounds. With
its new mechanism of action, the DDS-04 series was rapidly
bactericidal and highly potent across globally diverse
Enterobacteriaceae strains in research studies, which included
multi-drug resistant isolates. Importantly, the DDS-04 series also
showed low propensity for resistance development and did not show
cross-resistance with existing classes of antibiotics, suggesting
that DDS-04 compounds have the potential to overcome known
resistance mechanisms. This profile makes the DDS-04 series
attractive for further development for the treatment of
Enterobacteriaceae infections.
“The DDS-04 series aligns with our antibiotic
strategy. There is a clear opportunity to improve patient outcomes
and a need for new mechanisms to deliver these improved outcomes
and also to help address the spread of antimicrobial resistance,”
commented Mr Glyn Edwards, Chief Executive Officer of
Summit. “We look forward to gathering further data to support
the selection of a preclinical candidate from the DDS-04
series.”
A copy of the presentation is available in the
Publications section of the Company’s website:
www.summitplc.com.
About
EnterobacteriaceaeEnterobacteriaceae are a family of
Gram-negative bacteria responsible for severe and often deadly
infections. They account for a significant fraction of cases across
conditions, including complicated urinary tract infections,
bloodstream infections and hospital-acquired pneumonias. Summit
estimates there are more than 1 million infections in the US
annually caused by Enterobacteriaceae across these three settings.
Increasing resistance of Enterobacteriaceae has rendered many
marketed antibiotics ineffective against these bacteria. Two of the
most alarming antibiotic resistance trends are extended-spectrum
beta-lactamase (ESBL)-producing Enterobacteriaceae and
carbapenem-resistant Enterobacteriaceae (CRE). ESBL is an enzyme
that allows bacteria to become resistant to a wide variety of
penicillin and cephalosporin antibiotics. ESBL-producing
Enterobacteriaceae account for an estimated 26,000 infections
annually in the US with 1,700 deaths, according to the US Centers
for Drug Control and Prevention (‘CDC’). CRE are resistant to
nearly all existing antibiotics, including carbapenems which are
considered the antibiotics of last resort. CRE account for an
estimated 9,000 infections per year in the US and 600 deaths,
according to the CDC.
About Summit Therapeutics Summit
Therapeutics is a leader in antibiotic innovation. Our new
mechanism antibiotics are designed to become the new standards of
care for the benefit of patients and create value for payors and
healthcare providers. We are currently developing new mechanism
antibiotics for infections caused by C. difficile, N. gonorrhoeae
and ESKAPE pathogens and are using our proprietary Discuva Platform
to expand our pipeline. For more information, visit
www.summitplc.com and follow us on Twitter @summitplc.
This announcement contains inside information
for the purposes of Article 7 of EU Regulation 596/2014 (MAR).
Contacts
Summit |
|
|
Glyn Edwards / Richard Pye (UK
office) |
Tel: |
44 (0)1235 443 951 |
Michelle Avery (US office) |
|
+1 617 225 4455 |
|
|
|
Cairn Financial Advisers LLP (Nominated
Adviser) |
Tel: |
+44 (0)20 7213 0880 |
Liam Murray / Tony Rawlinson |
|
|
|
|
|
N+1 Singer (Joint Broker) |
Tel: |
+44 (0)20 7496 3000 |
Aubrey Powell / Jen Boorer, Corporate FinanceTom
Salvesen, Corporate Broking |
|
|
|
|
|
Bryan Garnier & Co Limited (Joint
Broker) |
Tel: |
+44 (0)20 7332 2500 |
Phil Walker / Dominic Wilson |
|
|
MSL Group (US) |
Tel: |
+1 781 684 6557 |
Jon Siegal |
|
summit@mslgroup.com |
|
|
|
Consilium Strategic Communications
(UK) |
Tel: |
+44 (0)20 3709 5700 |
Mary-Jane Elliott / Sue Stuart / Jessica Hodgson
/ |
|
summit@consilium-comms.com |
Lindsey Neville |
|
|
Summit Forward-looking Statements
Any statements in this press release about the
Company’s future expectations, plans and prospects, including but
not limited to, statements about the clinical and preclinical
development of the Company’s product candidates, the therapeutic
potential of the Company’s product candidates, the potential
commercialisation of the Company’s product candidates, the
sufficiency of the Company’s cash resources, the timing of
initiation, completion and availability of data from clinical
trials, the potential submission of applications for marketing
approvals and other statements containing the words "anticipate,"
"believe," "continue," "could," "estimate," "expect," "intend,"
"may," "plan," "potential," "predict," "project," "should,"
"target," "would," and similar expressions, constitute
forward-looking statements within the meaning of The Private
Securities Litigation Reform Act of 1995. Actual results may differ
materially from those indicated by such forward-looking statements
as a result of various important factors, including: the
uncertainties inherent in the initiation of future clinical trials,
availability and timing of data from ongoing and future clinical
trials and the results of such trials, whether preliminary results
from a clinical trial will be predictive of the final results of
that trial or whether results of early clinical trials or
preclinical studies will be indicative of the results of later
clinical trials, expectations for regulatory approvals, laws and
regulations affecting government contracts and funding awards,
availability of funding sufficient for the Company’s foreseeable
and unforeseeable operating expenses and capital expenditure
requirements and other factors discussed in the "Risk Factors"
section of filings that the Company makes with the Securities and
Exchange Commission, including the Company’s Annual Report on Form
20-F for the fiscal year ended 31 January 2019. Accordingly,
readers should not place undue reliance on forward-looking
statements or information. In addition, any forward-looking
statements included in this press release represent the Company’s
views only as of the date of this release and should not be relied
upon as representing the Company’s views as of any subsequent date.
The Company specifically disclaims any obligation to update any
forward-looking statements included in this press release.
-END-
Summit Therapeutics (NASDAQ:SMMT)
Historical Stock Chart
From Feb 2024 to Mar 2024
Summit Therapeutics (NASDAQ:SMMT)
Historical Stock Chart
From Mar 2023 to Mar 2024